Skip to main content
PRNBinactive

Principia Biopharma Inc.

Biopharma developer (SEC filing verified)·Phase 3·CEO: Martin Babler
OncologyNeurologyImmunologyDermatologyHematology

PRNB evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for PRNB—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

8.7/10

BioSniper Score

Based on 4 of 6 signals

Market Cap

—

Cash Runway

36.2 mo

Lead Asset

prn1008 (Phase 3)

Next Catalyst

—

Financial data as of Jun 30, 2020.

Tracking 4 pipeline candidates · 5 clinical trials for Principia Biopharma Inc..

Run Principia Biopharma Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Principia Biopharma Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 4 of 6 signals · derived from public data

Cash Runway10.0

36.2 months

Financial Health9.2

D/E 0.10 · 6% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth7.2

4 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Run my thesis on this company

Pipeline

Run my thesis on this company

Regulatory

Run my thesis on this company

Financials

Run my thesis on this company

Frequently asked questions

What is Principia Biopharma Inc.'s lead drug candidate?

Principia Biopharma Inc.'s most advanced tracked candidate is prn1008 (Phase 3) for Immune thrombocytopenic purpura (ITP).

Who is the CEO of Principia Biopharma Inc.?

Martin Babler is the chief executive officer of Principia Biopharma Inc. (PRNB).

What therapeutic areas does Principia Biopharma Inc. focus on?

Principia Biopharma Inc. develops therapies across Oncology, Neurology, Immunology, Dermatology, Hematology.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.